Motesanib is an orally administered multikinase inhibitor of VEGFR-1/2/3, PDGFRα/β, c-Kit, and RET, and was considered a potent anti-NSCLC drug in Asian patients based on the MONET1 trial.190 However, the results of a later phase III trial (NCT02629848) evaluating the efficacy of motesanib plus paclitaxel and carboplatin were disappointing. Here, PDGFRA is linked to non-small cell lung carcinoma.